Market Analysis
Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results
Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.
Total Stories
7
News
Moderna
Section
Moderna
Market Analysis
Why Is Moderna (MRNA) Stock Rising Today? $2.25B Patent Settlement
Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used in its COVID-19 vaccine.
Market Analysis
Why is Moderna’s Stock Gaining in Premarket Trading Today?
Moderna stock jumped in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine.
Market Analysis
Trump Admin. Reconsiders $590M Funding for Moderna’s Bird Flu Vaccine
The Trump administration is reconsidering a $590 million contract with Moderna for bird flu vaccine development.
Market Analysis
Moderna Cuts 2025 Sales Forecast Amid Low Vaccine Demand, Stock Plummets
Moderna has lowered its 2025 sales forecast due to decreased demand for its Covid and RSV vaccines.
Earnings
Nasdaq-100 Shakeup: 3 Stocks that Can Gain
Three stocks have their price targets above current price levels.
Market Analysis
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
Moderna announced plans to slash its R&D budget by $1.1 billion by 2027.